

*New 4-thiazolidinones from 5-ethyl
pyridine-2-ethanol: their antibacterial,
antifungal, and antitubercular activity*

**Navin B. Patel, Hemant R. Patel,
Faiyazalam M. Shaikh & Dhanji Rajani**

Medicinal Chemistry Research

ISSN 1054-2523

Med Chem Res

DOI 10.1007/s00044-013-0736-8



Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media New York. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

New 4-thiazolidinones from 5-ethyl pyridine-2-ethanol: their antibacterial, antifungal, and antitubercular activity

Navin B. Patel · Hemant R. Patel · Faiyazalam M. Shaikh · Dhanji Rajani

Received: 14 March 2013 / Accepted: 17 August 2013
© Springer Science+Business Media New York 2013

Abstract New thiazolidinones **5a–o** were prepared from Schiff base **4a–o** and thioglycolic acid in the presence of $ZnCl_2$ from 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde. The structures of the synthesized compounds were assigned on the basis of elemental analysis, IR, 1H NMR ^{13}C NMR, and mass spectral data. All the compounds were screened against different strains of bacteria and fungi. Compounds **4e**, **4n**, **4m**, **4o**, **5e**, **5f**, **5j**, and **5m** possessed very good activity against bacterial and fungal species. These active compounds impelled us to study their antitubercular activity. Schiff base **4n** and **4e** showed *M. tuberculosis* MIC value 25 and 62.5 $\mu g/ml$, respectively. Thiazolidinone **5m** displayed *M. tuberculosis* MIC at 25 $\mu g/ml$, which is better antitubercular activity compared with rifampicin.

Keywords Schiff base · Thiazolidinone · Antitubercular · Antibacterial · Antifungal

Introduction

An extensive research work on thiazolidinones has been done in the past. Synthesis of novel thiazolidinones was opted for the research due to their commercial and medicinal importance. They have been synthesized by the condensation of amino and aldehyde group containing molecules via

the intermediacy of a Schiff base, employing conventional methodologies. Schiff base also possessed various biological activities like antimicrobial, antibacterial, antifungal (Ronad *et al.*, 2009; Ansari and Lal, 2009; Panneerselvam *et al.*, 2009; Bharti *et al.*, 2010), antitubercular (Raparti *et al.*, 2009; Kamel *et al.*, 2010), analgesic, and anti-inflammatory activity (Bhandari *et al.*, 2008). The thiazolidinone nucleus is well known as wonder nucleus with wide variety of biological activities such as antimicrobial (Vicini *et al.*, 2006; Fuloria *et al.*, 2009; Mulwad *et al.*, 2009; Patel and Rathod, 2007; Patel and Patel, 2007; Patel and Patel, 2009a, b; Shah and Desai, 2007; Petrikaite *et al.*, 2007; Sattigeri *et al.*, 2005; Kavitha *et al.*, 2006; Saeed *et al.*, 2007; Sayyed *et al.*, 2006), antitubercular, antiviral and anticancer activity (Tatar *et al.*, 2008), anti-inflammatory, analgesic, CNS depressant, Muscle relaxant, and antipyretic activity (Kumar *et al.*, 2007; Gurupadayya *et al.*, 2008; Tarnalli *et al.*, 2008; Ottana *et al.*, 2005). They also possessed anti-HIV, antiproliferative, AT1 angiotensin-II (AII) receptor antagonists activity (Rawal *et al.*, 2007; Kucukguzel *et al.*, 2006; Shreenivas *et al.*, 2009; Chandrappa *et al.*, 2008).

The structure of pioglitazone HCl (Fig. 1) is well known for its anti-diabetic activity because of 1,3-thiazolidine-2,4-dione ring attached to the (4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde). It is evident from the literature survey that very little work done on thiazolidinones from pioglitazone HCl or its intermediate. In continuation of our work on pyridine and thiazolidinones earlier, we have reported antimicrobial and antitubercular activity (Patel and Patel, 2009a, b, 2010a, b; Patel *et al.*, 2010a, b; Patel and Shaikh, 2010).

In chemotherapeutic point of view, the design of new agents by molecular hybridization with multiple potential targets has always been a very attractive strategy for medicinal chemists (Barbosa *et al.*, 2011). In a view of these data, we report in this paper the synthesis of

N. B. Patel (✉) · H. R. Patel · F. M. Shaikh · D. Rajani
Department of Chemistry, Veer Narmad South Gujarat
University, Surat 395007, Gujarat, India
e-mail: drnavin@satyam.net.in

H. R. Patel
e-mail: hemantpatel1785@yahoo.co.in

F. M. Shaikh
e-mail: faiyaz_online007@yahoo.co.in




Fig. 1 Pioglitazone HCl




Fig. 2 Final thiazolidinones

thiazolidinones (Fig. 2), cyclized from Schiff base of 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde and studied their antimicrobial and antitubercular activity.


Results and discussion

Chemistry

The synthesis of Schiff bases and thiazolidinones was performed shown in (Scheme 1). Schiff bases **4a–o** were

synthesized by condensing 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde with appropriate aromatic amine in absolute alcohol and 2–3 drops of glacial acetic acid at refluxed temperature. The cyclic thiazolidinone **5a–o** was synthesized from appropriate Schiff base and thioglycolic acid in the presence of ZnCl_2 . The purity of the compounds was checked by TLC and elemental analysis. Spectral data (IR, ^1H NMR, ^{13}C NMR and Mass) of all the compounds were in full agreement with the proposed structures.

The compounds **4a–o** were confirmed by the IR, NMR, and Mass spectra. In the IR spectrum, the band of $-\text{CH}=\text{N}$ observed at $1,627\text{ cm}^{-1}$, the asymmetric and symmetric band of $\text{C}-\text{O}-\text{C}$ ether linkage observed at $1,227$ and $1,046\text{ cm}^{-1}$. A singlet observed at δ 8.25 attributed to the $-\text{CH}=\text{N}$ protons and triplet at δ 4.30 confirmed the $-\text{CH}_2-\text{O}-$. The higher resonance at δ 160.8 ppm was attributed to the $-\text{CH}$ group present in Schiff base. Molecular ion peak observed at m/z 345, confirmed its molecular weight of **4o**. Disappearance of $-\text{CH}=\text{N}$ band at $1,627\text{ cm}^{-1}$ and appearance of $1,760\text{ cm}^{-1}$ of $-\text{C}=\text{O}$ (thiazolidinone) was observed in IR, signal at δ 3.20 and δ 5.30 for the $-\text{CH}_2-$ and $-\text{CH}$ of cyclic thiazolidinone observed in ^1H NMR, and $-\text{C}=\text{O}$ carbon appeared at δ 170.1 was also observed in ^{13}C NMR and molecular ion peak at m/z 419 of **5o** confirmed its molecular weight.



R:	a. 4-F	b. 3,5-F	c. 4-Cl	d. 3,4-Cl	e. 2,4-Cl
	f. 3,4-F	g. 2-Br, 4-F	h. 3-Cl, 4-CH ₃	i. 3,5-Cl	j. 2-Cl
	k. 2-F	l. 2,5-Cl	m. 2,3-Cl	n. 3-Cl	o. 4-CH ₃

Scheme 1 Synthetic route for 4-thiazolidinones from 5-ethylpyridine-ethanol **5a–o**

Antimicrobial activity

Methods

All MTCC cultures were collected from Institute of Microbial Technology, Chandigarh and tested against known drugs ampicillin and griseofulvin. Mueller–Hinton broth was used as nutrient medium to grow and dilute the drug suspension for the test. Inoculum size for test strain was adjusted to 10^8 CFU (Colony Forming Unit) per milliliter by comparing the turbidity. DMSO was used as diluents to get desired concentration of drugs to test upon standard bacterial strains. Serial dilutions were prepared in primary and secondary screening. The control tube containing no antibiotic was immediately sub cultured (before inoculation) by spreading a loopful evenly over a quarter of plate of medium suitable for the growth of the test organism and put for incubation at 37 °C overnight. The tubes were then incubated overnight. The MICs of compounds were carried out by broth microdilution method as described by Rattan (2000). Antibacterial activity was screened against two gram positive (*Staphylococcus aureus* MTCC 96, *Streptococcus pyogenes* MTCC 443) and two gram negative (*Escherichia coli* MTCC 442, *Pseudomonas aeruginosa* MTCC 2488) bacteria, ampicillin was used as a standard antibacterial agent. Antifungal activity was screened against three fungal species *Candida albicans* MTCC 227, *Aspergillus niger* MTCC 282 and *Aspergillus clavatus* MTCC 1323, griseofulvin was used as a standard antifungal agent.

Antibacterial activity

The minimum Inhibitory concentrations (MIC) of the tested compounds **4a–o** and **5a–o** are shown in (Table 1). From the screening data, most of the compounds possessed very good antibacterial activity (MIC, 100–250 µg/ml) against *S. aureus*; some of them possessed better activity compared to ampicillin.

Schiff bases **4e** and **4n** containing mono and dichloro substituents possessed pronounced activity (100 µg/ml) against *E. coli*. Compound **4e** displayed better activity (100 µg/ml) against *P. aeruginosa* due to 2,4-dichloro substituent. Compounds **4g**, **4l**, **4m**, and **4o** containing 2-bromo-4-fluoro, 2,5-dichloro, 2,3-dichloro, and 4-methyl substituents exhibited significant activity in the range of (100–200 µg/ml) against *S. aureus* which indicates that these compounds are very effective toward the bacteria. Remaining compounds **4d**, **4e**, **4h**, **4k**, and **4n** having 3,4-dichloro, 2,4-dichloro, 3-chloro, 4-methyl, 2-fluoro, and 3-chloro substituents showed comparable to moderate activity (100–500 µg/ml) against reference drug. The thiazolidinones **5e**, **5m**, **5f**, and **5j** having 2,4-dichloro, 2,3-dichloro, 3,4-difluoro, and 2-chloro substituents showed higher activity (62.5–100 µg/ml) against

Table 1 Antibacterial activity of **4a–o** and **5a–o**

Compounds	Minimal bactericidal concentration (µg/ml)			
	Gram negative		Gram positive	
	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>	<i>S. pyogenus</i>
4a	250	500	500	500
4b	500	500	1,000	1,000
4c	1,000	1,000	1,000	1,000
4d	200	250	250	250
4e	100	100	250	500
4f	250	250	500	500
4g	250	250	200	250
4h	500	500	250	500
4i	1,000	1,000	500	500
4j	500	500	500	500
4k	250	200	250	500
4l	500	250	150	200
4m	250	200	100	250
4n	100	150	250	250
4o	150	200	100	250
5a	250	250	500	500
5b	200	150	200	500
5c	250	500	250	500
5d	500	500	250	250
5e	62.5	100	200	250
5f	100	150	150	200
5g	250	500	500	500
5h	250	500	500	500
5i	500	500	150	200
5j	100	200	250	250
5k	150	250	250	250
5l	250	250	200	200
5m	62.5	200	100	100
5n	500	500	500	500
5o	500	500	250	250
Ampicillin	100	100	250	100

E. coli. Compound **5e** having 2,4-dichloro substituent possessed better activity (100 µg/ml) against *P. aeruginosa*. Compounds **5b**, **5c**, **5d**, **5e**, **5f**, **5i**, **5j**, **5k**, **5l**, **5m**, and **5o** having monochloro, dichloro, fluoro, and methyl substituents displayed better activity (100–250 µg/ml) against *S. aureus*. Compound **5m** having 2,3-dichloro substituent is found to be very active (MIC value of 100 µg/ml) against *S. pyogenus*. Remaining compounds possessed moderate-to-weak activity against all four bacterial species.

Antifungal activity

MIC of compounds **4a–o** and **5a–o** are summarized in (Table 2). Most of the compounds possessed very good

Table 2 Antifungal activity of **4a–o** and **5a–o**

Compounds	Minimal fungicidal concentration ($\mu\text{g/ml}$)		
	<i>C. albicans</i>	<i>A. niger</i>	<i>A. clavatus</i>
4a	500	>1,000	>1,000
4b	>1,000	1,000	1,000
4c	>1,000	>1,000	>1,000
4d	200	500	500
4e	250	500	500
4f	500	>1,000	>1,000
4g	500	500	1,000
4h	500	1,000	1,000
4i	>1,000	>1,000	>1,000
4j	1,000	1,000	1,000
4k	500	500	500
4l	500	1,000	1,000
4m	500	1,000	>1,000
4n	1,000	1,000	1,000
4o	>1,000	>1,000	>1,000
5a	1,000	500	500
5b	1,000	1,000	1,000
5c	500	1,000	1,000
5d	1,000	500	500
5e	250	250	500
5f	1,000	>1,000	>1,000
5g	500	500	500
5h	1,000	1,000	>1,000
5i	500	1,000	1,000
5j	1,000	1,000	>1,000
5k	100	250	250
5l	1,000	1,000	1,000
5m	500	500	500
5n	1,000	1,000	>1,000
5o	1000	500	500
Nystatin	100	100	100
Greseofulvin	500	100	100

antifungal activity against *C. albicans*; their MIC values were in the range between 100 and 500 $\mu\text{g/ml}$.

Schiff base **4a**, **4d**, **4e**, **4f**, **4g**, **4h**, **4k**, **4l**, and **4m** possessed better activity of (200–500 $\mu\text{g/ml}$) against *C. albicans* which is due to 4-fluoro, 3,4-dichloro, 2,4-dichloro, 3,4-difluoro, 2-bromo-4-fluoro, 3-chloro-4-methyl, 2,5-chloro, and 2,3-dichloro substituents, whereas remaining Schiff bases possessed weak activity against *A. niger* and *A. clavatus*. Thiazolidinones **5c**, **5e**, **5g**, **5i**, and **5m** containing 4-chloro, 2,4-dichloro, 2-bromo-4-fluoro, 3,5-dichloro, and 2,3-dichloro substituents possessed good activity of (250–500 $\mu\text{g/ml}$) against *C. albicans*. Compound **5k** having 2-fluoro substituent showed significant activity (100 $\mu\text{g/ml}$) against nystatin, whereas remaining

Table 3 Antimycobacterial activity of **4a–o** and **5a–o**

Compounds	MIC values ($\mu\text{g/ml}$)	% Inhibition
	of <i>M. tuberculosis</i> H ₃₇ Rv	
4e	62.5	98
4n	25	95
4m	500	97
4o	125	95
5e	>1,000	95
5f	250	96
5j	100	98
5m	25	99
Rifampicin	40	99

compounds possessed weak activity against *A. niger* and *A. clavatus*.

Antitubercular activity

The encouraging results from the antibacterial studies impelled us to go for preliminary screening against *M. tuberculosis*; the results are summarized in (Table 3). In this screening, 1,000, 500, and 250 $\mu\text{g/ml}$ concentrations of the compounds were taken. The active compounds found in this screening were further tested in a secondary screening against *M. tuberculosis* H₃₇Rv in L. J. Medium (conventional method). The compounds found active in primary screening were similarly diluted to obtain 200, 100, 50, 25, 12.5, 6.250, and 3.50 $\mu\text{g/ml}$ concentrations. The antitubercular activity data were compared with rifampicin at a 40 $\mu\text{g/ml}$ concentration. Schiff base, **4n** having 3-chloro group showed *M. tuberculosis* MIC value 25 $\mu\text{g/ml}$ which is very active as rifampicin which have standard concentration 40 $\mu\text{g/ml}$. Compounds **4e** containing 2,4-dichloro substituent showed *M. tuberculosis* MIC value in the range between 62.5 $\mu\text{g/ml}$. Thiazolidinone **5m** having 2,3-dichloro substituent displayed MIC value 25 $\mu\text{g/ml}$ which indicate better activity. The highest dilution showing at least 95–99 % inhibition growth is taken as MIC. Remaining compounds showed moderate-to-weak activity against H₃₇Rv strain.

Conclusions

Compounds **5e** and **5m** possessed excellent activity of 62.5 $\mu\text{g/ml}$ comparable to ampicillin. Compound **5k** showed remarkable activity of 100 $\mu\text{g/ml}$ comparable to nystatin. Compound bearing fluoro, chloro, and disubstituted chloro are more effective to inhibit the both bacterial and fungal species. Compound **4n** and **5m** having chloro and dichloro substituents exhibited *M. tuberculosis* MIC

value 25 µg/ml comparable with rifampicin. From this observations, we can conclude that halogen groups can impart a positive effect for biological activity i.e., activity increasing effect. Present work will be useful for understanding antimicrobial and antitubercular activity of hybrids of thiazolidinones and pyridine.

Experimental

Laboratory Chemicals were supplied by Rankem India Ltd. and Fischer Scientific Ltd. Melting points were determined by the open tube capillary method and are uncorrected. The purity of the compounds was determined by thin layer chromatography (TLC) plates (silica gel G) in the solvent system toluene:ethyl acetate (7.5:2.5). The spots were observed by exposure to iodine vapors or by UV light. The IR spectra were obtained on a Perkin–Elmer 1720 FT-IR spectrometer (KBr pellets). The ¹H NMR and ¹³C NMR spectra were recorded on a Bruker Avance II 400 spectrometer using TMS as the internal standard in CDCl₃. Elemental analysis of the newly synthesized compounds were carried out on Carlo Erba 1108 analyzer. The mass spectra were recorded on micromass Q-T of micro (TOF MS ES⁺).

Procedure for the synthesis of 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde (3)

4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzaldehyde (3) was synthesized by the method described in the literature (Gaonkar *et al.*, 2006).

General preparation of the compounds (4a–o)

A mixture of 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde (0.01 mol) and aromatic amine (0.01 mol) was taken in absolute ethanol and few drops of glacial acetic acid were added. Then, the mixture was refluxed for 6–8 h on water bath. The completion of reaction was monitored by TLC (toluene:ethyl acetate, 7.5:2.5). The excess solvent was distilled off, and then remaining residue poured into ice cold water. The separated solid was filtered, washed, and recrystallized from ethanol to give product 4a–o (Fig. 3).




Fig. 3 Schiff base 4a–o

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-4-fluorobenzenamine (4a)

This compound was obtained as off white solid, yield: 70 %, M.P. 85–87 °C, *R*_f: 0.45; IR (KBr): 3055 (Ar–H), 2956, 2844 (–CH₂–), 1628 (–CH=N), 1227, 1045 (C–O–C), 972 (C–F); ¹H NMR (CDCl₃): δ 1.12 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.50 (q, *J* = 8.0 Hz, 2H, –CH₂–), 3.17 (t, *J* = 7.0 Hz, 2H, –CH₂–), 4.32 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 7.00–7.87 (m, 8H, Ar–H), 7.34–8.34 (m, 3H, Pyridine-H), 8.27 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.4 (C₈), 32.5 (C₇), 37.5 (C₉), 67.6 (C₁₀), 115.2–155.4 (C₁₁–C₁₆), 116.5–161.4 (C₁₈–C₂₃), 123.3–157.3 (C₂–C₆), 160.6 (C₁₇); MS (*m/z*): 348 (M⁺); Anal. Calcd. for C₂₂H₂₁N₂OF: C, 75.84; H, 6.08; N, 8.04; Found C, 75.82; H, 6.09; N, 8.05.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-3,5-difluorobenzenamine (4b)

This compound was obtained as off white solid, yield: 72 %, M.P. 100–103 °C, *R*_f: 0.43; IR (KBr): 3058 (Ar–H), 2958, 2845 (–CH₂–), 1627 (–CH=N), 1228, 1046 (C–O–C), 974 (C–F); ¹H NMR (CDCl₃): δ 1.13 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.52 (q, *J* = 8.0 Hz, 2H, –CH₂–), 3.15 (t, *J* = 7.0 Hz, 2H, –CH₂–), 4.33 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 6.72–7.85 (m, 7H, Ar–H), 7.34–8.36 (m, 3H, Pyridine-H), 8.26 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.7 (C₈), 32.6 (C₇), 37.5 (C₉), 67.3 (C₁₀), 115.2–155.4 (C₁₁–C₁₆), 123.7–151.3 (C₁₈–C₂₃), 123.2–157.6 (C₂–C₆), 160.7 (C₁₇); MS (*m/z*): 366 (M⁺); Anal. Calcd. for C₂₂H₂₀N₂OF₂: C, 72.12; H, 5.50; N, 7.65; Found C, 72.13; H, 5.51; N, 7.62.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-4-chlorobenzenamine (4c)

This compound was obtained as off yellow solid, yield: 80 %, M.P. 113–115 °C, *R*_f: 0.47; IR (KBr): 3056 (Ar–H), 2960, 2844 (–CH₂–), 1626 (–CH=N), 1227, 1044 (C–O–C), 745 (C–Cl); ¹H NMR (CDCl₃): δ 1.15 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.54 (q, *J* = 8.0 Hz, 2H, –CH₂–), 3.16 (t, *J* = 7.0 Hz, 2H, –CH₂–), 4.30 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 7.05–7.87 (m, 8H, Ar–H), 7.35–8.35 (m, 3H, Pyridine-H), 8.28 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.7 (C₈), 32.6 (C₇), 37.5 (C₉), 67.3 (C₁₀), 115.2–155.4 (C₁₁–C₁₆), 123.7–151.3 (C₁₈–C₂₃), 123.2–157.6 (C₂–C₆), 160.7 (C₁₇); MS (*m/z*): 364 (M⁺), 366 (M+2); Anal. Calcd. for C₂₂H₂₁N₂OCl: C, 72.42; H, 5.80; N, 7.68; Found C, 72.41; H, 5.79; N, 7.66.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-3,4-dichlorobenzenamine (4d)

This compound was obtained as off yellow liquid, yield: 78 %, M.P. semi solid, *R*_f: 0.43; IR (KBr): 3057 (Ar–H),

2957, 2845 (–CH₂–), 1629 (–CH=N), 1228, 1046 (C–O–C), 746 (C–Cl); ¹H NMR (CDCl₃): δ 1.14 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.56 (q, *J* = 8.0 Hz, 2H, –CH₂), 3.13 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.33 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 7.09–7.86 (m, 7H, Ar–H), 7.33–8.35 (m, 3H, Pyridine-H), 8.25 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.6 (C₈), 32.5 (C₇), 37.7 (C₉), 67.4 (C₁₀), 115.4–155.6 (C₁₁–C₁₆), 121.8–152.6 (C₁₈–C₂₃), 123.4–157.4 (C₂–C₆), 160.5 (C₁₇); MS (*m/z*): 398 (M⁺), 400 (M+2), 402 (M+4); Anal. Calcd. for C₂₂H₂₀N₂OCl₂: C, 66.17; H, 5.05; N, 7.02; Found C, 66.15; H, 5.04; N, 7.00.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-2,4-dichlorobenzeneamine (**4e**)

This compound was obtained as off yellow liquid, yield: 75 %, M.P. semi solid, *R*_f: 0.50; IR (KBr): 3056 (Ar–H), 2957, 2847 (–CH₂–), 1624 (–CH=N), 1227, 1043 (C–O–C), 745 (C–Cl); ¹H NMR (CDCl₃): δ 1.13 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.54 (q, *J* = 8.0 Hz, 2H, –CH₂), 3.15 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.35 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 6.70–7.88 (m, 7H, Ar–H), 7.34–8.35 (m, 3H, Pyridine-H), 8.26 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.4 (C₈), 32.6 (C₇), 37.5 (C₉), 67.5 (C₁₀), 115.3–155.7 (C₁₁–C₁₆), 125.1–141.3 (C₁₈–C₂₃), 123.5–157.3 (C₂–C₆), 160.4 (C₁₇); MS (*m/z*): 398 (M⁺), 400 (M+2), 402 (M+4); Anal. Calcd. for C₂₂H₂₀N₂OCl₂: C, 66.17; H, 5.05; N, 7.02; Found C, 66.16; H, 5.06; N, 7.01.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-3,4-difluorobenzeneamine (**4f**)

This compound was obtained as yellow solid, yield: 68 %, M.P. 120–122 °C, *R*_f: 0.51; IR (KBr): 3059 (Ar–H), 2954, 2845 (–CH₂–), 1626 (–CH=N), 1226, 1045 (C–O–C), 973 (C–F); ¹H NMR (CDCl₃): δ 1.16 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.53 (q, *J* = 8.0 Hz, 2H, –CH₂), 3.13 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.36 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 6.89–7.85 (m, 7H, Ar–H), 7.34–8.37 (m, 3H, Pyridine-H), 8.25 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.7 (C₈), 32.4 (C₇), 37.6 (C₉), 67.6 (C₁₀), 115.0–155.5 (C₁₁–C₁₆), 111.2–150.3 (C₁₈–C₂₃), 123.1–157.4 (C₂–C₆), 160.8 (C₁₇); MS (*m/z*): 366 (M⁺); Anal. Calcd. for C₂₂H₂₀N₂O₂F₂: C, 72.12; H, 5.50; N, 7.65; Found C, 72.11; H, 5.51; N, 7.64.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-2-bromo-4-fluorobenzeneamine (**4g**)

This compound was obtained as off brown liquid, yield: 59 %, M.P. semi solid, *R*_f: 0.46; IR (KBr): 3056 (Ar–H), 2955, 2844 (–CH₂–), 1627 (–CH=N), 1225, 1046 (C–O–C), 972 (C–F), 857 (C–Br); ¹H NMR (CDCl₃): δ 1.14 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.57 (q, *J* = 8.0 Hz, 2H, –CH₂),

3.16 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.34 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 6.89–7.86 (m, 7H, Ar–H), 7.30–8.38 (m, 3H, Pyridine-H), 8.27 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.8 (C₈), 32.5 (C₇), 37.4 (C₉), 67.7 (C₁₀), 115.2–155.3 (C₁₁–C₁₆), 112.6–163.5 (C₁₈–C₂₃), 123.2–157.6 (C₂–C₆), 160.7 (C₁₇); MS (*m/z*): 426 (M⁺), 428 (M+2); Anal. Calcd. for C₂₂H₂₀N₂O₂Br: C, 61.84; H, 4.72; N, 6.56; Found C, 61.80; H, 4.71; N, 6.53.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-3-chloro-4-methylbenzeneamine (**4h**)

This compound was obtained as off brown solid, yield: 62 %, M.P. 135–137 °C, *R*_f: 0.48; IR (KBr): 3058 (Ar–H), 2958, 2845 (–CH₂–), 1628 (–CH=N), 1228, 1046 (C–O–C), 744 (C–Cl); ¹H NMR (CDCl₃): δ 1.18 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.35 (s, *J* = 8.0 Hz, 3H, –CH₃), 2.58 (q, *J* = 7.0 Hz, 2H, –CH₂), 3.15 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.33 (t, 2H, –CH₂–O), 7.00–7.82 (m, 7H, Ar–H), 7.35–8.36 (m, 3H, Pyridine-H), 8.24 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.6 (C₈), 20.1 (C₂₄), 32.6 (C₇), 37.6 (C₉), 67.5 (C₁₀), 115.8–155.4 (C₁₁–C₁₆), 120.0–151.5 (C₁₈–C₂₃), 123.4–157.8 (C₂–C₆), 160.3 (C₁₇); MS (*m/z*): 378 (M⁺), 380 (M+2); Anal. Calcd. for C₂₃H₂₃N₂OCl: C, 72.91; H, 6.12; N, 7.39; Found C, 72.90; H, 6.10; N, 7.36.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-3,5-dichlorobenzeneamine (**4i**)

This compound was obtained as off yellow solid, yield: 77 %, M.P. 110–112 °C, *R*_f: 0.43; IR (KBr): 3056 (Ar–H), 2956, 2843 (–CH₂–), 1627 (–CH=N), 1224, 1045 (C–O–C), 746 (C–Cl); ¹H NMR (CDCl₃): δ 1.17 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.58 (q, *J* = 8.0 Hz, 2H, –CH₂), 3.15 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.33 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 7.05–7.84 (m, 7H, Ar–H), 7.35–8.36 (m, 3H, Pyridine-H), 8.24 (s, 1H, –CH=N–); ¹³C NMR (CDCl₃): δ 15.6 (C₈), 32.6 (C₇), 37.6 (C₉), 67.5 (C₁₀), 115.8–155.4 (C₁₁–C₁₆), 120.5–156.1 (C₁₈–C₂₃), 123.4–157.6 (C₂–C₆), 160.5 (C₁₇); MS (*m/z*): 398 (M⁺), 400 (M+2), 402 (M+4); Anal. Calcd. for C₂₂H₂₀N₂OCl₂: C, 66.17; H, 5.05; N, 7.02; Found C, 66.18; H, 5.04; N, 7.04.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-2-chlorobenzeneamine (**4j**)

This compound was obtained as brown liquid, yield: 78 %, M.P. semi solid, *R*_f: 0.44; IR (KBr): 3057 (Ar–H), 2957, 2846 (–CH₂–), 1627 (–CH=N), 1229, 1047 (C–O–C), 745 (C–Cl); ¹H NMR (CDCl₃): δ 1.15 (t, *J* = 8.0 Hz, 3H, –CH₃), 2.56 (q, *J* = 8.0 Hz, 2H, –CH₂), 3.14 (t, *J* = 7.0 Hz, 2H, –CH₂), 4.34 (t, *J* = 7.0 Hz, 2H, –CH₂–O), 7.08–7.82 (m, 8H, Ar–H), 7.34–8.37 (m, 3H, Pyridine-H), 8.22 (s, 1H,

–CH=N–); ^{13}C NMR (CDCl_3): δ 15.4 (C_8), 32.5 (C_7), 37.7 (C_9), 67.6 (C_{10}), 115.5–155.3 (C_{11} – C_{16}), 123.–143.4 (C_{18} – C_{23}), 123.5–157.3 (C_2 – C_6), 160.2 (C_{17}); MS (m/z): 364 (M^+), 366 ($\text{M}+2$); Anal. Calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{OCl}$: C, 72.42; H, 5.80; N, 7.68; Found C, 72.44; H, 5.81; N, 7.67.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-2-fluorobenzenamine (**4k**)

This compound was obtained as brown liquid, yield, 69 %, M.P. semi solid, R_f : 0.47; IR (KBr): 3056 (Ar–H), 2958, 2845 (– CH_2 –), 1627 (–CH=N), 1227, 1048 (C–O–C), 975 (C–F); ^1H NMR (CDCl_3): δ 1.16 (t, $J = 8.0$ Hz, 3H, – CH_3), 2.57 (q, $J = 8.0$ Hz, 2H, – CH_2), 3.16 (t, $J = 7.0$ Hz, 2H, – CH_2), 4.36 (t, $J = 7.0$ Hz, 2H, – CH_2 –O), 7.00–7.85 (m, 8H, Ar–H), 7.35–8.38 (m, 3H, Pyridine-H), 8.24 (s, 1H, –CH=N–); ^{13}C NMR (CDCl_3): δ 15.1 (C_8), 32.5 (C_7), 37.2 (C_9), 67.5 (C_{10}), 115.4–155.4 (C_{11} – C_{16}), 116.8–153.2 (C_{18} – C_{23}), 123.4–157.4 (C_2 – C_6), 160.3 (C_{17}); MS (m/z): 348 (M^+); Anal. Calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{OF}$: C, 75.84; H, 6.08; N, 8.04; Found C, 75.82; H, 6.06; N, 8.03.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-2,5-dichlorobenzenamine (**4l**)

This compound was obtained as brown liquid, yield: 75 %, M.P. semi solid, R_f : 0.42; IR (KBr): 3059 (Ar–H), 2955, 2845 (– CH_2 –), 1629 (–CH=N), 1225, 1049 (C–O–C), 746 (C–Cl); ^1H NMR (CDCl_3): δ 1.19 (t, $J = 8.0$ Hz, 3H, – CH_3), 2.53 (q, $J = 8.0$ Hz, 2H, – CH_2), 3.17 (t, $J = 7.0$ Hz, 2H, – CH_2), 4.37 (t, $J = 7.0$ Hz, 2H, – CH_2 –O), 7.06–7.88 (m, 7H, Ar–H), 7.33–8.36 (m, 3H, Pyridine-H), 8.26 (s, 1H, –CH=N–); ^{13}C NMR (CDCl_3): δ 15.3 (C_8), 32.6 (C_7), 37.4 (C_9), 67.6 (C_{10}), 115.5–155.6 (C_{11} – C_{16}), 124.0–144.6 (C_{18} – C_{23}), 123.5–157.7 (C_2 – C_6), 160.7 (C_{17}); MS (m/z): 398 (M^+), 400 ($\text{M}+2$), 402 ($\text{M}+4$); Anal. Calcd. for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{OCl}_2$: C, 66.17; H, 5.05; N, 7.02; Found C, 66.15; H, 5.03; N, 7.04.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-2,3-dichlorobenzenamine (**4m**)

This compound was obtained as brown liquid, yield: 71 %, M.P. semi solid, R_f : 0.43; IR (KBr): 3056 (Ar–H), 2957, 2845 (– CH_2 –), 1627 (–CH=N), 1227, 1046 (C–O–C), 746 (C–Cl); ^1H NMR (CDCl_3): δ 1.20 (t, $J = 8.0$ Hz, 3H, – CH_3), 2.58 (q, $J = 8.0$ Hz, 2H, – CH_2), 3.15 (t, $J = 7.0$ Hz, 2H, – CH_2), 4.35 (t, $J = 7.0$ Hz, 2H, – CH_2 –O), 7.07–7.83 (m, 7H, Ar–H), 7.32–8.36 (m, 3H, Pyridine-H), 8.28 (s, 1H, –CH=N–); ^{13}C NMR (CDCl_3): δ 15.4 (C_8), 32.4 (C_7), 37.7 (C_9), 67.5 (C_{10}), 115.2–155.4 (C_{11} – C_{16}), 121.8–144.6 (C_{18} – C_{23}), 123.2–157.4 (C_2 – C_6), 160.5 (C_{17}); MS (m/z): 398 (M^+), 400 ($\text{M}+2$), 402 ($\text{M}+4$); Anal.

Calcd. for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{OCl}_2$: C, 66.17; H, 5.05; N, 7.02; Found C, 66.16; H, 5.04; N, 7.03.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-3-chlorobenzenamine (**4n**)

This compound was obtained as brown liquid, yield: 76 %, M.P. semi solid, R_f : 0.51; IR (KBr): 3056 (Ar–H), 2956, 2846 (– CH_2 –), 1626 (–CH=N), 1226, 1046 (C–O–C), 744 (C–Cl); ^1H NMR (CDCl_3): δ 1.24 (t, $J = 8.0$ Hz, 3H, – CH_3), 2.52 (q, $J = 8.0$ Hz, 2H, – CH_2), 3.15 (t, $J = 7.0$ Hz, 2H, – CH_2), 4.32 (t, $J = 7.0$ Hz, 2H, – CH_2 –O), 7.03–8.23 (m, 8H, Ar–H), 7.33–8.34 (m, 3H, Pyridine-H), 8.27 (s, 1H, –CH=N–); ^{13}C NMR (CDCl_3): δ 15.7 (C_8), 32.5 (C_7), 37.6 (C_9), 67.6 (C_{10}), 115.3–155.7 (C_{11} – C_{16}), 120.4–154.6 (C_{18} – C_{23}), 123.5–157.5 (C_2 – C_6), 160.6 (C_{17}); MS (m/z): 364 (M^+), 366 ($\text{M}+2$); Anal. Calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{OCl}$: C, 72.42; H, 5.80; N, 7.68; Found C, 72.43; H, 5.82; N, 7.69.

N-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)-4-methylbenzenamine (**4o**)

This compound was obtained as off white solid, yield: 70 %, M.P. 80–83 °C, R_f : 0.52; IR (KBr): 3056 (Ar–H), 2957, 2845 (– CH_2 –), 1627 (–CH=N), 1227, 1046 (C–O–C); ^1H NMR (CDCl_3): δ 1.13 (t, $J = 8.0$ Hz, 3H, – CH_3), 2.24 (s, $J = 8.0$ Hz, 3H, – CH_3), 2.52 (q, $J = 7.0$ Hz, 2H, – CH_2), 3.17 (t, $J = 7.0$ Hz, 2H, – CH_2), 4.29 (t, 2H, – CH_2 –O), 6.85–7.69 (m, 8H, Ar–H), 7.34–8.30 (m, 3H, Pyridine-H), 8.25 (s, 1H, –CH=N–); ^{13}C NMR (CDCl_3): δ 15.4 (C_8), 25.7 (C_{24}), 32.4 (C_7), 37.4 (C_9), 67.4 (C_{10}), 115.2–155.3 (C_{11} – C_{16}), 120.8–148.9 (C_{18} – C_{23}), 123.4–158.9 (C_2 – C_6), 161.4 (C_{17}); MS (m/z): 345 (M^+); Anal. Calcd. for $\text{C}_{23}\text{H}_{24}\text{N}_2\text{O}$: C, 80.20; H, 7.02; N, 8.13; Found C, 80.22; H, 7.03; N, 8.11.

General preparation of the compounds (**5a–o**)

A mixture of compound **4a–o** (0.01 mol) and thioglycolic acid (0.02 mol) in the presence of ZnCl_2 and solvent 1,4-dioxane was refluxed for 12–16 h. The completion of reaction was monitored by TLC (toluene:ethyl acetate, 7.5:2.5) and reaction mass was dumped in ice cold water. The resulting product was treated with 5 % NaHCO_3 solution to remove unreacted traces of thioglycolic acid.




Fig. 4 Thiazolidinones **5a–o**

The separated solid was washed with water, dried and recrystallized from ethanol to give product **5a–o** (Fig. 4).

3-(4-Fluorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5a)

This compound was obtained as off yellow solid, yield: 65 %, M.P. 110–112 °C, R_f : 0.65; IR (KBr): 3031 (Ar–H), 2955, 2834 (–CH₂–), 1715 (–C=O of thiazolidinone), 1223, 1044 (C–O–C), 975 (C–F); ¹H NMR (CDCl₃): δ 1.17 (t, $J = 8.0$ Hz, 3H, –CH₃), 2.54 (q, $J = 8.0$ Hz, 2H, –CH₂), 3.22 (s, 2H, –CH₂), 3.53 (t, $J = 7.0$ Hz, 2H, –CH₂), 4.20 (t, $J = 7.0$ Hz, 2H, –CH₂–O), 5.32 (s, 1H, –CH), 6.65–7.83 (m, 8H, Ar–H), 7.34–8.34 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.5 (C₈), 32.3 (C₇), 33.4 (C₁₈), 36.5 (C₉), 65.6 (C₁₇), 68.4 (C₁₀), 114.5–156.8 (C₁₁–C₁₆), 115.7–158.5 (C₂₀–C₂₅), 123.4–157.5 (C₂–C₆), 170.4 (C₁₉); MS (m/z): 422 (M⁺); Anal. Calcd. for C₂₄H₂₃N₂O₂F₂S: C, 68.22; H, 5.49; N, 6.63; Found C, 68.21; H, 5.51; N, 6.64.

3-(3,5-Difluorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5b)

This compound was obtained as yellow solid, yield: 67 %, M.P. 95–97 °C, R_f : 0.69; IR (KBr): 3034 (Ar–H), 2950, 2832 (–CH₂–), 1717 (–C=O of thiazolidinone), 1220, 1041 (C–O–C), 973 (C–F); ¹H NMR (CDCl₃): δ 1.14 (t, $J = 8.0$ Hz, 3H, –CH₃), 2.52 (q, $J = 8.0$ Hz, 2H, –CH₂), 3.21 (s, 2H, –CH₂), 3.52 (t, $J = 7.0$ Hz, 2H, –CH₂), 4.23 (t, $J = 7.0$ Hz, 2H, –CH₂–O), 5.34 (s, 1H, –CH), 6.58–7.84 (m, 7H, Ar–H), 7.35–8.32 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.2 (C₈), 32.4 (C₇), 33.6 (C₁₈), 36.6 (C₉), 65.3 (C₁₇), 68.5 (C₁₀), 114.2–156.3 (C₁₁–C₁₆), 100.3–164.7 (C₂₀–C₂₅), 123.6–157.8 (C₂–C₆), 170.6 (C₁₉); MS (m/z): 440 (M⁺); Anal. Calcd. for C₂₄H₂₂N₂O₂F₂S: C, 65.44; H, 5.03; N, 6.36; Found C, 65.42; H, 5.02; N, 6.37.

3-(4-Chlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5c)

This compound was obtained as off brown solid, yield: 69 %, M.P. 125–128 °C, R_f : 0.66; IR (KBr): 3038 (Ar–H), 2952, 2834 (–CH₂–), 1719 (–C=O of thiazolidinone), 1222, 1043 (C–O–C), 743 (C–Cl); ¹H NMR (CDCl₃): δ 1.18 (t, $J = 8.0$ Hz, 3H, –CH₃), 2.54 (q, $J = 8.0$ Hz, 2H, –CH₂), 3.24 (s, 2H, –CH₂), 3.53 (t, $J = 7.0$ Hz, 2H, –CH₂), 4.25 (t, $J = 7.0$ Hz, 2H, –CH₂–O), 5.35 (s, 1H, –CH), 6.65–7.84 (m, 8H, Ar–H), 7.38–8.37 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.3 (C₈), 32.5 (C₇), 33.3 (C₁₈), 36.5 (C₉), 65.6 (C₁₇), 68.7 (C₁₀), 114.5–156.6 (C₁₁–C₁₆), 123.0–139.7 (C₂₀–C₂₅), 123.5–157.9 (C₂–C₆), 170.4 (C₁₉); MS (m/z): 438 (M⁺), 440 (M+2); Anal. Calcd. for

C₂₄H₂₃N₂O₂ClS: C, 65.67; H, 5.28; N, 6.38; Found C, 65.65; H, 5.29; N, 6.36.

3-(3,4-Dichlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5d)

This compound was obtained as brown solid, yield: 68 %, M.P. 140–142 °C, R_f : 0.65; IR (KBr): 3040 (Ar–H), 2951, 2833 (–CH₂–), 1714 (–C=O of thiazolidinone), 1226, 1046 (C–O–C), 745 (C–Cl); ¹H NMR (CDCl₃): δ 1.15 (t, $J = 8.0$ Hz, 3H, –CH₃), 2.56 (q, $J = 8.0$ Hz, 2H, –CH₂), 3.23 (s, 2H, –CH₂), 3.56 (t, $J = 7.0$ Hz, 2H, –CH₂), 4.27 (t, $J = 7.0$ Hz, 2H, –CH₂–O), 5.31 (s, 1H, –CH), 6.60–7.80 (m, 7H, Ar–H), 7.37–8.36 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.6 (C₈), 32.7 (C₇), 33.4 (C₁₈), 36.3 (C₉), 65.2 (C₁₇), 68.5 (C₁₀), 114.1–156.2 (C₁₁–C₁₆), 121.0–141.2 (C₂₀–C₂₅), 123.3–157.7 (C₂–C₆), 170.2 (C₁₉); MS (m/z): 472 (M⁺), 474 (M+2), 476 (M+4); Anal. Calcd. for C₂₄H₂₂N₂O₂Cl₂S: C, 60.89; H, 4.68; N, 5.92; Found C, 60.88; H, 4.69; N, 5.93.

3-(2,4-Dichlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5e)

This compound was obtained as brown solid, yield: 66 %, M.P. 145–146 °C, R_f : 0.68; IR (KBr): 3038 (Ar–H), 2952, 2834 (–CH₂–), 1716 (–C=O of thiazolidinone), 1225, 1045 (C–O–C), 746 (C–Cl); ¹H NMR (CDCl₃): δ 1.17 (t, $J = 8.0$ Hz, 3H, –CH₃), 2.54 (q, $J = 8.0$ Hz, 2H, –CH₂), 3.24 (s, 2H, –CH₂), 3.55 (t, $J = 7.0$ Hz, 2H, –CH₂), 4.25 (t, $J = 7.0$ Hz, 2H, –CH₂–O), 5.32 (s, 1H, –CH), 6.62–7.86 (m, 7H, Ar–H), 7.36–8.37 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.8 (C₈), 32.4 (C₇), 33.6 (C₁₈), 36.4 (C₉), 65.3 (C₁₇), 68.4 (C₁₀), 114.3–156.4 (C₁₁–C₁₆), 124.4–138.2 (C₂₀–C₂₅), 123.7–157.8 (C₂–C₆), 170.3 (C₁₉); MS (m/z): 472 (M⁺), 474 (M+2), 476 (M+4); Anal. Calcd. for C₂₄H₂₂N₂O₂Cl₂S: C, 60.89; H, 4.68; N, 5.92; Found C, 60.87; H, 4.70; N, 5.93.

3-(3,4-Difluorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5f)

This compound was obtained as off yellow solid, yield: 70 %, M.P. 170–173 °C, R_f : 0.67; IR (KBr): 3033 (Ar–H), 2953, 2835 (–CH₂–), 1713 (–C=O of thiazolidinone), 1223, 1046 (C–O–C), 977 (C–F); ¹H NMR (CDCl₃): δ 1.19 (t, $J = 8.0$ Hz, 3H, –CH₃), 2.55 (q, $J = 8.0$ Hz, 2H, –CH₂), 3.26 (s, 2H, –CH₂), 3.56 (t, $J = 7.0$ Hz, 2H, –CH₂), 4.24 (t, $J = 7.0$ Hz, 2H, –CH₂–O), 5.34 (s, 1H, –CH), 6.67–7.74 (m, 7H, Ar–H), 7.38–8.38 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.5 (C₈), 32.6 (C₇), 33.3 (C₁₈), 36.7 (C₉), 65.6 (C₁₇), 68.5 (C₁₀), 114.3–156.7 (C₁₁–C₁₆), 111.7–149.7 (C₂₀–C₂₅), 123.6–157.5 (C₂–C₆), 170.6 (C₁₉);

MS (*m/z*): 440 (M^+); Anal. Calcd. for $C_{24}H_{22}N_2O_2F_2S$: C, 65.44; H, 5.03; N, 6.36; Found C, 65.45; H, 5.01; N, 6.37.

3-(2-Bromo-4-fluorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (**5g**)

This compound was obtained as off brown solid, yield: 56 %, M.P. 186–187 °C, R_f : 0.67; IR (KBr): 3037 (Ar–H), 2955, 2832 (–CH₂–), 1712 (–C=O of thiazolidinone), 1228, 1046 (C–O–C), 855 (C–Br) 975 (C–F); ¹H NMR (CDCl₃): δ 1.15 (t, J = 8.0 Hz, 3H, –CH₃), 2.56 (q, J = 8.0 Hz, 2H, –CH₂), 3.25 (s, 2H, –CH₂) 3.57 (t, J = 7.0 Hz, 2H, –CH₂), 4.22 (t, J = 7.0 Hz, 2H, –CH₂–O), 5.33 (s, 1H, –CH), 6.66–7.78 (m, 7H, Ar–H), 7.36–8.36 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.4 (C₈), 32.5 (C₇), 33.5 (C₁₈), 36.8 (C₉), 65.2 (C₁₇), 68.3 (C₁₀), 114.5–156.4 (C₁₁–C₁₆), 114.7–160.7 (C₂₀–C₂₅), 123.5–157.4 (C₂–C₆), 170.7 (C₁₉); MS (*m/z*): 502 (M^+), 504 ($M+2$); Anal. Calcd for $C_{24}H_{22}N_2O_2FSBr$: C, 57.49; H, 4.42; N, 5.59; Found C, 57.52; H, 4.44; N, 5.61.

3-(3-Chloro-4-methylphenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (**5h**)

This compound was obtained as dark brown solid, yield: 61 %, M.P. 191–193 °C, R_f : 0.62; IR (KBr): 3034 (Ar–H), 2954, 2836 (–CH₂–), 1715 (–C=O of thiazolidinone), 1220, 1043 (C–O–C), 747 (C–Cl); ¹H NMR (CDCl₃): δ 1.13 (t, J = 8.0 Hz, 3H, –CH₃), 2.20 (s, 3H, –CH₃), 2.53 (q, J = 8.0 Hz, 2H, –CH₂), 3.23 (s, 2H, –CH₂) 3.52 (t, J = 7.0 Hz, 2H, –CH₂), 4.27 (t, J = 7.0 Hz, 2H, –CH₂–O), 5.32 (s, 1H, –CH), 6.62–7.80 (m, 8H, Ar–H), 7.35–8.34 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.5 (C₈), 25.7 (C₂₆), 32.6 (C₇), 33.7 (C₁₈), 36.6 (C₉), 65.2 (C₁₇), 68.3 (C₁₀), 114.4–156.5 (C₁₁–C₁₆), 119.6–140.1 (C₂₀–C₂₅), 123.4–157.4 (C₂–C₆), 170.3 (C₁₉); MS (*m/z*): 452 (M^+), 454 ($M+2$); Anal. Calcd for $C_{25}H_{25}N_2O_2ClS$: C, 66.28; H, 5.56; N, 6.18; Found C, 66.26; H, 5.57; N, 6.20.

3-(3,5-Dichlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (**5i**)

This compound was obtained as off brown solid, yield: 68 %, M.P. 155–157 °C, R_f : 0.65; IR (KBr): 3036 (Ar–H), 2957, 2834 (–CH₂–), 1714 (–C=O of thiazolidinone), 1223, 1045 (C–O–C), 746 (C–Cl); ¹H NMR (CDCl₃): δ 1.16 (t, J = 8.0 Hz, 3H, –CH₃), 2.58 (q, J = 8.0 Hz, 2H, –CH₂), 3.24 (s, 2H, –CH₂) 3.54 (t, J = 7.0 Hz, 2H, –CH₂), 4.24 (t, J = 7.0 Hz, 2H, –CH₂–O), 5.32 (s, 1H, –CH), 6.64–7.87 (m, 7H, Ar–H), 7.37–8.37 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.6 (C₈), 32.4 (C₇), 33.6 (C₁₈), 36.3 (C₉), 65.5 (C₁₇), 68.0 (C₁₀), 114.0–156.2 (C₁₁–C₁₆), 120.1–135.9 (C₂₀–C₂₅), 123.0–157.5 (C₂–C₆), 170.3 (C₁₉);

MS (*m/z*): 472 (M^+), 474 ($M+2$), 476 ($M+4$); Anal. Calcd. for $C_{24}H_{22}N_2O_2Cl_2S$: C, 60.89; H, 4.68; N, 5.92; Found C, 60.88; H, 4.69; N, 5.93.

3-(2-Chlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (**5j**)

This compound was obtained as brown solid, yield: 72 %, M.P. 130–132 °C, R_f : 0.69; IR (KBr): 3034 (Ar–H), 2955, 2835 (–CH₂–), 1717 (–C=O of thiazolidinone), 1225, 1046 (C–O–C), 748 (C–Cl); ¹H NMR (CDCl₃): δ 1.17 (t, J = 8.0 Hz, 3H, –CH₃), 2.57 (q, J = 8.0 Hz, 2H, –CH₂), 3.23 (s, 2H, –CH₂) 3.56 (t, J = 7.0 Hz, 2H, –CH₂), 4.25 (t, J = 7.0 Hz, 2H, –CH₂–O), 5.34 (s, 1H, –CH), 6.58–7.81 (m, 8H, Ar–H), 7.36–8.39 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.2 (C₈), 32.5 (C₇), 33.7 (C₁₈), 36.6 (C₉), 65.4 (C₁₇), 68.4 (C₁₀), 114.5–156.6 (C₁₁–C₁₆), 123.0–140.2 (C₂₀–C₂₅), 123.4–157.1 (C₂–C₆), 170.4 (C₁₉); MS (*m/z*): 438 (M^+), 440 ($M+2$); Anal. Calcd. for $C_{24}H_{23}N_2O_2ClS$: C, 65.67; H, 5.28; N, 6.38; Found C, 65.65; H, 5.26; N, 6.39.

3-(2-Fluorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (**5k**)

This compound was obtained as yellow liquid, yield: 75 %, M.P. semi solid, R_f : 0.63; IR (KBr): 3041 (Ar–H), 2950, 2831 (–CH₂–), 1711 (–C=O of thiazolidinone), 1226, 1042 (C–O–C), 972 (C–F); ¹H NMR (CDCl₃): δ 1.20 (t, J = 8.0 Hz, 3H, –CH₃), 2.53 (q, J = 8.0 Hz, 2H, –CH₂), 3.25 (s, 2H, –CH₂) 3.54 (t, J = 7.0 Hz, 2H, –CH₂), 4.28 (t, J = 7.0 Hz, 2H, –CH₂–O), 5.33 (s, 1H, –CH), 6.63–7.88 (m, 8H, Ar–H), 7.38–8.38 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.6 (C₈), 32.8 (C₇), 33.4 (C₁₈), 36.5 (C₉), 65.7 (C₁₇), 68.5 (C₁₀), 114.8–156.4 (C₁₁–C₁₆), 115.7–127.8 (C₂₀–C₂₅), 123.3–157.5 (C₂–C₆), 170.5 (C₁₉); MS (*m/z*): 422 (M^+); Anal. Calcd. for $C_{24}H_{23}N_2O_2FS$: C, 68.22, H, 5.49, N, 6.63; found C, 68.24, H, 5.52, N, 6.65.

3-(2,5-Dichlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (**5l**)

This compound was obtained as brown liquid, yield: 63 %, M.P. semi solid, R_f : 0.64; IR (KBr): 3032 (Ar–H), 2954, 2836 (–CH₂–), 1713 (–C=O of thiazolidinone), 1225, 1043 (C–O–C), 743 (C–Cl); ¹H NMR (CDCl₃): δ 1.21 (t, J = 8.0 Hz, 3H, –CH₃), 2.51 (q, J = 8.0 Hz, 2H, –CH₂), 3.23 (s, 2H, –CH₂) 3.55 (t, J = 7.0 Hz, 2H, –CH₂), 4.25 (t, J = 7.0 Hz, 2H, –CH₂–O), 5.34 (s, 1H, –CH), 6.60–7.90 (m, 7H, Ar–H), 7.35–8.36 (m, 3H, Pyridine-H); ¹³C NMR (CDCl₃): δ 20.3 (C₈), 32.2 (C₇), 33.5 (C₁₈), 36.6 (C₉), 65.8 (C₁₇), 68.1 (C₁₀), 114.4–156.3 (C₁₁–C₁₆), 123.4–141.6 (C₂₀–C₂₅), 123.6–157.4 (C₂–C₆), 170.4 (C₁₉);

MS (*m/z*): 472 (M^+), 474 ($M+2$), 476 ($M+4$); Anal. Calcd. for $C_{24}H_{22}N_2O_2Cl_2S$: C, 60.89; H, 4.68; N, 5.92; Found C, 60.90; H, 4.67; N, 5.90.

3-(2,3-Dichlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5m)

This compound was obtained as brown liquid, yield: 65 %, M.P. semi solid, R_f : 0.66; IR (KBr): 3036 (Ar-H), 2958, 2838 ($-CH_2-$), 1718 ($-C=O$ of thiazolidinone), 1223, 1045 (C-O-C), 747 (C-Cl); 1H NMR ($CDCl_3$): δ 1.15 (t, $J = 8.0$ Hz, 3H, $-CH_3$), 2.54 (q, $J = 8.0$ Hz, 2H, $-CH_2-$), 3.24 (s, 2H, $-CH_2-$), 3.52 (t, $J = 7.0$ Hz, 2H, $-CH_2-$), 4.23 (t, $J = 7.0$ Hz, 2H, $-CH_2-O$), 5.35 (s, 1H, $-CH$), 6.56–7.79 (m, 7H, Ar-H), 7.36–8.37 (m, 3H, Pyridine-H); ^{13}C NMR ($CDCl_3$): δ 20.6 (C_8), 32.5 (C_7), 33.6 (C_{18}), 36.4 (C_9), 65.5 (C_{17}), 68.3 (C_{10}), 114.3–156.7 ($C_{11}-C_{16}$), 121.1–141.6 ($C_{20}-C_{25}$), 123.2–157.3 (C_2-C_6), 170.6 (C_{19}); MS (*m/z*): 472 (M^+), 474 ($M+2$), 476 ($M+4$); Anal. Calcd. for $C_{24}H_{22}N_2O_2Cl_2S$: C, 60.89; H, 4.68; N, 5.92; Found C, 60.87; H, 4.67; N, 5.93.

3-(3-Chlorophenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5n)

This compound was obtained as brown limpid, yield: 74 %, M.P. semi solid, R_f : 0.63; IR (KBr): 3035 (Ar-H), 2955, 2836 ($-CH_2-$), 1715 ($-C=O$ of thiazolidinone), 1224, 1047 (C-O-C), 744 (C-Cl); 1H NMR ($CDCl_3$): δ 1.17 (t, $J = 8.0$ Hz, 3H, $-CH_3$), 2.56 (q, $J = 8.0$ Hz, 2H, $-CH_2-$), 3.25 (s, 2H, $-CH_2-$), 3.55 (t, $J = 7.0$ Hz, 2H, $-CH_2-$), 4.25 (t, $J = 7.0$ Hz, 2H, $-CH_2-O$), 5.34 (s, 1H, $-CH$), 6.67–7.81 (m, 8H, Ar-H), 7.37–8.34 (m, 3H, Pyridine-H); ^{13}C NMR ($CDCl_3$): δ 20.7 (C_8), 32.4 (C_7), 33.3 (C_{18}), 36.8 (C_9), 65.7 (C_{17}), 68.4 (C_{10}), 114.4–156.6 ($C_{11}-C_{16}$), 119.7–143.1 ($C_{20}-C_{25}$), 123.4–157.6 (C_2-C_6), 170.3 (C_{19}); MS (*m/z*): 438 (M^+), 440 ($M+2$); Anal. Calcd. for $C_{24}H_{23}N_2O_2ClS$: C, 65.67; H, 5.28; N, 6.38; Found C, 65.66; H, 5.29; N, 6.37.

3-(4-Methylphenyl)-2-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)thiazolidin-4-one (5o)

This compound was obtained as yellow solid, yield: 67 %, M.P. 99–101 °C, R_f : 0.68; IR (KBr): 3033 (Ar-H), 2958, 2838 ($-CH_2-$), 1710 ($-C=O$ of thiazolidinone), 1225, 1042 (C-O-C); 1H NMR ($CDCl_3$): δ 1.15 (t, $J = 8.0$ Hz, 3H, $-CH_3$), 2.16 (s, 3H, $-CH_3$), 2.51 (q, $J = 8.0$ Hz, 2H, $-CH_2-$), 3.20 (s, 2H, $-CH_2-$), 3.50 (t, $J = 7.0$ Hz, 2H, $-CH_2-$), 4.25 (t, $J = 7.0$ Hz, 2H, $-CH_2-O$), 5.30 (s, 1H, $-CH$), 6.85–7.70 (m, 8H, Ar-H), 7.33–8.31 (m, 3H, Pyridine-H); ^{13}C NMR ($CDCl_3$): δ 20.9 (C_8), 25.6 (C_{26}), 32.4 (C_7), 33.5 (C_{18}), 36.4 (C_9), 65.4 (C_{17}), 68.1 (C_{10}), 114.6–156.7 ($C_{11}-$

C_{16}), 120.6–137.2 ($C_{20}-C_{25}$), 123.1–157.2 (C_2-C_6), 170.1 (C_{19}); MS (*m/z*): 419 (M^+); Anal. Calcd. for $C_{25}H_{26}N_2O_2S$: C, 71.74; H, 6.26; N, 6.69; Found C, 71.76; H, 6.25; N, 6.70.

Acknowledgments The authors thank Department of Chemistry for laboratory facilities, the Librarian of Veer Narmad South Gujarat University, Surat for library facilities. We also thank C.D.R.I., Lucknow for elemental analysis, and S.A.I.F., Chandigarh for 1H NMR, ^{13}C NMR and mass spectral analysis.

References

- Ansari KF, Lal C (2009) Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents. *Eur J Med Chem* 44:2294–2299
- Barbosa TP, Sousa SCO, Amorim FM, Rodrigues YKS, de Assis PAC, Caldas JPA, Oliveira MR, Vasconcellos MLAA (2011) Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach. *Bioorg Med Chem* 19:4250–4256
- Bhandari SV, Bothara KG, Raut MK, Patil AA, Sarkate AP, Mokale VJ (2008) Design, synthesis and evaluation of anti-inflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives. *Bioorg Med Chem* 16: 1822–1831
- Bharti SK, Nath G, Tilak R, Singh SK (2010) Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2,4-disubstituted thiazole ring. *Eur J Med Chem* 45:651–660
- Chandrupa S, Prasad SBB, Vinaya K, Kumar CSA, Thimmegowda NR, Rangappa KS (2008) Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methylbenzylidene)-thiazolidine-2,4-diones. *Invest New Drugs* 26: 437–444
- Fuloria N, Singh V, Yar MS, Ali M (2009) Synthesis, characterization and antimicrobial evaluation of novel imines and thiazolidinones. *Acta Polo Pharma Drug Res* 66:141–146
- Gaonkar SL, Rai KML, Prabhuswamy B (2006) Synthesis and antimicrobial studies of a new series of 2-[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]-5-substituted-1,3,4-oxadiazoles. *Eur J Med Chem* 41:841–846
- Gurupadaya BM, Gopal M, Padmashali B, Manohara YN (2008) Synthesis and pharmacological evaluation of azetidin-2-ones and thiazolidin-4-ones encompassing benzothiazole. *Ind J Pharm Sci* 70(577):572
- Kamel MM, Ali HI, Anwar MM, Mohamed NA, Soliman AM (2010) Synthesis, antitumor activity and molecular docking study of novel sulfonamide-Schiff's bases, thiazolidinones, benzothiazinones and their C-nucleoside derivatives. *Eur J Med Chem* 45:572–580
- Kavitha CV, Basappa Swamy SN, Mantelingu K, Doreswamy S, Sridhar MA, Prasad JS, Kanchugarakoppal Rangappa S (2006) Synthesis of new bioactive venlafaxine analogs: novel thiazolidin-4-ones as antimicrobials. *Bioorg Med Chem* 14:2290–2299
- Kucukguzel G, Kocatepe A, Clercq ED, Sahin F, Gulluce M (2006) Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. *Eur J Med Chem* 41:353–359
- Kumar A, Rajput C, Bhati S (2007) Synthesis of 3-[4'-(p-chlorophenyl)-thiazol-2'-yl]-2-[(substituted) azetidinone/thiazolidinone]-amino-methyl]-6-bromoquinazolin-4-ones as anti-inflammatory agent. *Bioorg Med Chem* 15:3089–3096

- Mulwad VV, Mir AA, Parmar HT (2009) Synthesis and antimicrobial screening of 5-benzylidene-2-imino-3-(2-oxo-2H-benzopyran-6-yl)-thiazolidin-4-one and its derivatives. *Ind J Chem* 48B:137–141
- Ottana R, Maccari R, Barreca ML, Bruno G, Rotondo A, Rossi A, Chiricosta G, Paola RD, Sautebin L, Cuzzocrea S, Vigorita MG (2005) 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents. *Bioorg Med Chem* 13:4243–4252
- Panneerselvam P, Rather BA, Reddy DRS, Kumar NR (2009) Synthesis and anti-microbial screening of some Schiff bases of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones. *Eur J Med Chem* 44:2328–2333
- Patel NB, Patel VN (2007) Synthesis and antimicrobial evaluation of new (4-oxo-thiazolidinyl)quinazolin-4(3H)ones of 2-[(2,6-dichlorophenyl)amino]phenylacetic acid. *Iran J Pharm Res* 6:251–258
- Patel NB, Patel SD (2009a) Synthesis and antimicrobial studies of some 4-thiazolidinone containing fluoroquinolones analogues. *Der Pharma Chemica* 1(2):199–209
- Patel NB, Patel HR (2009b) Synthesis and pharmacological studies of 5-ethyl pyridin-2-ethanol analogs derivatives. *Arkivoc* 12:302–321
- Patel NB, Patel HR (2010a) Design and synthesis of 2-(5-ethylpyridine-2-yl) ethanol analogs as potential microbial agents. *Int J Drug Design Discov* 1:93–106
- Patel NB, Patel SD (2010b) Synthesis and antimicrobial study of fluoroquinolonebased 4-thiazolidinones. *Med Chem Res*. doi:10.1007/s00044-009-9228-2
- Patel NB, Rathod RD (2007) Synthesis and antimicrobial studies of analogues of intermediate of sildenafil. *J Saudi Chem Soc* 11:93–100
- Patel NB, Shaikh FM (2010) Synthesis and anti microbial studies of new pyridine analogs 4-thiazolidinones containing 2-amino-6-methoxybenzothiazole. *Saudi Pharma J* 18(3):129–136. doi:10.1016/j.jsps.2010.05.002
- Patel NB, Khan IH, Rajani S (2010a) Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles. *Eur J Med Chem* 45:4293–4299. doi:10.1016/j.ejmech.2010.06.031
- Patel NB, Patel VN, Patel HR, Shaikh FM, Patel JC (2010b) Synthesis and microbial studies of (4-oxo-thiazolidinyl) sulfonamides bearing quinazolin-4(3H)-ones. *Acta Polo Pharma Drug Res* 67:267–275
- Petrikaite V, Tarasevicius E, Pavilonis A (2007) New thiazolidinones-4 with sulfamethizole-2 substituent as potential antifungal and antimicrobial preparations. *Biologija* 53:45–50
- Raparti V, Chitre T, Bothara K, Kumar V, Dangre S, Khachane C, Gore S, Deshmane B (2009) Novel 4-(morpholin-4-yl)-N0-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations. *Eur J Med Chem* 44:3954–3960
- Rattan A (2000) Antimicrobials in laboratory medicine. Churchill B I Livingstone, New Delhi, pp 85–108
- Rawal RK, Tripathi R, Katti SB, Pannecouque C, Clercq ED (2007) Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. *Bioorg Med Chem* 15:1725–1731
- Ronad PM, Noolvi MN, Sapkal S, Dharbhamulla S, Maddi VS (2010) Synthesis and antimicrobial activity of 7-(2-substituted phenylthiazolidinyl)-benzopyran-2-one derivatives. *Eur J Med Chem* 45:85–89. doi:10.1016/j.ejmech.2009.09.028
- Saeed N, Abbas N, Florke U (2007) Synthesis and antibacterial activity of some novel 2-arylimino-3-aryl-thiazolidin-4-ones. *J Braz Chem Soc* 18:559–565
- Sattigeri VJ, Soni A, Singhal S, Khan S, Pandya M, Bhateja P, Mathur T, Rattan A, Khanna JM, Mehta A (2005) Synthesis and antimicrobial activity of novel thiazolidinones. *Arkivoc* 2:46–59
- Sayed M, Mokle S, Bokhare M, Mankar A, Surwase S, Bhusare S, Vibhutea Y (2006) Synthesis of some new 2,3-diaryl-1,3-thiazolidin-4-ones as antibacterial agents. *Arkivoc* 2:187–192
- Shah TJ, Desai VA (2007) Synthesis of some novel fluorinated 4-thiazolidinones containing amide linkages and their antimicrobial screening. *Arkivoc* 16:218–228
- Shreenivas MT, Chetan BP, Bhat AR (2009) Synthesis and pharmacological evaluation of certain schiff bases and thiazoldine derivatives as AT1 angiotension-II(AII) receptor antagonists. *J Pharma Sci Tech* 1:88–94
- Tarnalli AD, Bhat AR, Srinivas S, Sarvanan E (2008) Antiinflammatory, analgesic and antipyretic activity of certain thiazolidinones. *Ind J Pharm Sci* 70:159–164
- Tatar E, Kucukguzel I, Clercq ED, Sahin F, Gulluce M (2008) Synthesis, characterization and screening of antimicrobial, antituberculosis, antiviral and anticancer activity of novel 1,3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-4-(methylthio)butyryl]-4-alkyl/arylalkyl thiosemicarbazides. *Arkivoc* 16:191–210
- Vicini P, Geronikaki A, Anastasia K, Incerti M, Zani F (2006) Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. *Bioorg Med Chem* 14:3859–3864